Basic Principles of Drug Discovery and Development 2e By Benjamin E. Blass

🌟 Introduction to Basic Principles of Drug Discovery and Development (2nd Ed.) by Benjamin E. Blass

The second edition of 「Basic Principles of Drug Discovery and Development」, authored by Dr. Benjamin E. Blass and published in April 2021 by Academic Press, represents a landmark contribution to the interdisciplinary education of drug research professionals and scholars ([Elsevier Shop][1]). This text is meticulously designed to guide upper-level undergraduates, graduate students, and early-career scientists through the intricate journey from initial hypothesis to market-ready therapeutic. Integrating theory, case studies, and practical insights, it bridges the realms of academia and industry with rare clarity.

🎯 Educational Objectives and Audience

Blass’ book assumes that while readers may be highly knowledgeable within their own domains—whether medicinal chemistry, pharmacology, biochemistry, or computational biology—they may lack a holistic understanding of drug discovery’s multidisciplinary flow. The text remedies this knowledge gap, empowering students and burgeoning researchers to speak fluently across diverse scientific languages. Its principal goal is to cultivate professionals capable of not only executing technical tasks but also collaborating effectively within multidisciplinary teams.

The book’s intended audience encompasses:

「Upper-level undergraduates and graduate students」 delving into drug discovery, pharmacokinetics, or toxicology;
「New industrial scientists」 who require a broad yet rigorous foundation;
「Academics」 seeking an applied overview of drug research and translation;
「Professionals」 in public policy, business, or venture capital who must grasp the pharmaceutical development ecosystem.

📚 Book Structure: Roadmap of Content

Spanning 13 comprehensive chapters (plus front matter and references), the book follows a logical, chronological path:

「Overview of Drug Research」 – Lays foundational principles and integrates modern methods and collaborative processes.
「History of Drug Discovery」 – From botanical remedies to biotechnology, this chapter contextualizes present-day approaches.
「Classical Drug Targets」 – Reviews enzymes, GPCRs, ion channels, transporters, and emerging targets.
「In Vitro Screening Methods」 – Introduces assay development, assay types (ELISA, FRET, patch clamp), and screening logic.
「Medicinal Chemistry Fundamentals」 – Explores SAR, pharmacophores, bioisosterism, and drug-likeness.
「ADME/Pharmacokinetics」 – Details absorption, distribution, metabolism, excretion methodologies, and PK study design.
「Animal Models」 – Surveys model selection, disease-state modeling, and validity concerns.
「Safety and Toxicology」 – Covers acute/chronic toxicity, genotoxicity, cardiovascular and CNS safety.
「Antibody and Biologic Discovery」 – Adds depth to biologic modalities and their discovery principles.
「Clinical Trial Design」 – Walks through phases I–IV, adaptive design, regulatory submissions, and trial methodologies.
「Translational Medicine & Biomarkers」 – Discusses biomarker validation, imaging tools, surrogate endpoints, and translational case histories.
「Industry Structure」 – Analyzes organizational forms, R&D team dynamics, and outsourcing strategies.
「Intellectual Property」 – Provides a primer on patent law, filing processes, priority, and patent landscapes.
「Case Studies」 – Real-world retrospectives on drugs such as Tamiflu, statins, protease inhibitors, and ADCs.

This structured layout guides readers from fundamental theory to real-world implementation, enhancing understanding at each stage.

🧭 Chapter Highlights and Insights

1. Drug Discovery Workflow

The opening chapter frames the drug pipeline—from hit identification to clinical trials—highlighting the roles of medicinal chemists, pharmacologists, toxicologists, clinicians, and regulatory scientists. It emphasizes collaborative strategies and the need for translational thinking.

2. Historical Context

By revisiting milestones such as Paul Ehrlich’s “magic bullet” concept, the Thalidomide tragedy, recombinant-DNA breakthroughs, and landmark FDA amendments (Hatch–Waxman, Biologics Price Competition and Innovation Act), blass provides a rich backdrop for current regulatory and scientific norms.

3. Drug Target Landscape

Chapter 3 categorizes major target classes—enzymes, GPCRs, ion channels, and transporters—with mechanistic detail, signaling cascades, and case-based target validation. It fosters nuanced target selection thinking.

4. In Vitro Screening

Sophisticated discrimination of assay formats is provided: ELISA, FRET, TRFRET, AlphaScreen™, fluorescence polarization, patch clamp, radioligand assays, label-free biosensors. Each modality is contextualized with the equation of IC\₅₀, K_d, K_i, and EC\₅₀ values.

5. Medicinal Chemistry Strategy

Blass introduces SAR and SPR, delves into quantitative SAR (QSAR), pharmacophoric design, chiral centers, lipophilicity/hydrophilicity balance, and Lipinski’s rule-of-five. Strategies in bioisosteres and drug-likeness are grounded in medicinal chemistry best practices.

6. ADME/PK

Comprehensive discussions on in vitro–in vivo correlation, clearance, bioavailability, half-life, volume of distribution, and transporter-mediated drug efflux support rational PK profiling strategies.

7. Animal Models

Animal model selection is methodically discussed across disease categories—oncology, infectious disease, neurology, cardiovascular pathologies—emphasizing construct and predictive validity, as well as ethical considerations that are becoming essential in modern biomedical research.

8. Safety and Toxicity

From acute versus chronic toxicity assays, MTD determination, cardiotoxicity panels (e.g., hERG), mutagenicity, teratogenicity, and drug–drug interactions, this chapter is indispensable for preclinical safety officers and translational teams. It reflects today’s regulatory scrutiny and risk frameworks.

9. Biologics

A new addition in the 2nd edition, this chapter navigates antibody structures, conjugates, Fc-engineering, and success stories of biologic drugs like ADCs and antibody–receptor modulators.

10. Clinical Trials

Readers gain insight into clinical trial design, dose escalation strategies (3+3, adaptive), regulatory filing requirements, endpoints, and post-marketing surveillance. This robust foundation is vital for translational scientists.

11. Translational Medicine

This chapter interconnects bench-to-bedside strategies through biomarker qualification, imaging (e.g., FDG-PET), and pharmacodynamic readouts, emphasizing case-based data linking like aprepitant PET validation for CNS target engagement.

12. Industry Overview

Blass dissects organizational structures—from large pharma to biotech startups—and contract research organizations (CROs), detailing funding streams, project teams, and the interplay between science and venture capital.

13. Intellectual Property

A concise yet powerful overview of patentability criteria, novelty, non-obviousness, patent filing components, and freedom-to-operate evaluations—crucial knowledge for emerging inventors and innovators.

14. Case Studies

Rich real-world examples drive home core drug discovery lessons:

「Tamiflu」: Mechanism-to-market journey;
「HDAC inhibitors」: Optimization and structural modifications;
「HIV protease inhibitors」: Complexity in combinatorial chemistry;
「COX‑2 inhibitors」: Metabolism, toxicity, and formulation;
「Nitrofurantoin」: Lessons in clinical success;
「Antihistamines」: Case comparisons like Seldane vs. Allegra;
「Parkinsonian neurotoxicity」: MPTP insights and translational caution.

These case studies illuminate decision-making at each stage—from hit-to-lead to late-stage dossier preparation.

🧑‍🔬 Author Profile: Benjamin E. Blass

Dr. Blass brings a rare duality of academic and industrial experience. With a career spanning roles at Wyeth, P&G Pharmaceuticals, Fox Chase Chemical Diversity Center, and Temple University’s School of Pharmacy, his perspective is both scientifically rigorous and pragmatically informed. Additionally, Blass holds credentials as a registered U.S. patent agent, enriching his discussions on IP strategy. This strong pedigree ensures that the material is scientifically current, industrially relevant, and legally nuanced.

🆕 Second Edition Enhancements

The updated edition, released April 19, 2021, integrates:

「Biologics & ADC discovery」: A new full chapter on biologics, reflecting their growing therapeutic importance.
「Formulation science」: Including nanotechnology, IV, and transdermal solutions.
「Computational methods」: Fragment-based design, structure-based screening, and in silico profiling.
「Case study expansion」: Modern examples spanning HTS successes and real-world translational mishaps.

These updates ensure that readers engage with cutting-edge methodology and current industrial complexities.

🎓 Why Students and Researchers Should Read This

「Multidisciplinary fluency」 – Offers a cohesive overview of pharmacology, medicinal chemistry, ADME, toxicology, and regulation.
「Translational vision」 – Teaches strategic thinking with target validation, biomarker development, and clinical endpoint selection.
「Regulatory and IP awareness」 – Prepares scientists to navigate FDA requirements and strategically safeguard intellectual property.
「Real‑world perspective」 – Embeds historical lessons and modern case studies to balance theory with tangible outcomes.
「Educational depth」 – Includes methodical questions at chapter endpoints to reinforce critical reflection.
「Ideal reference」 – Serves equally well for coursework, early-career reference, or as a refresher on industrial drug development.

🧭 Practical Classroom & Lab Applications

Educators and course directors can integrate this text into curriculum through:

「Targeted reading sections」 for pharmacology, ADME, or translational courses;
「Structured case study seminars」, where students evaluate real candidate progression;
「Group discussions」 on assay development, IP strategy, preclinical model selection, or clinical trial ethics;
「Capstone projects」 employing integrated pipeline design, from initial target rationale to regulatory submission strategies.

✅ Conclusion

In summary, Basic Principles of Drug Discovery and Development (2nd Ed.) by Benjamin E. Blass offers an unparalleled marriage of depth, clarity, and practical insight. It empowers students and early-career researchers to synthesize knowledge across disciplines—chemistry, biology, pharmacology, regulation, and business—while providing a robust scaffold for multidisciplinary collaboration. The enhanced focus on biologics, formulation, and computational drug design in this edition reflects the most current trends and ensures the text's relevance for years to come.

For aspiring drug developers, translational scientists, and research educators aiming to equip students with a professional, industry-aligned perspective, this volume is an essential resource 📘.

Embrace this text as both a guide and a toolkit—cultivating the next generation of scientists capable of navigating the continuum from molecule to medicine.

❝
You can get E-book via Link
Basic Principles of Drug Discovery and Development
❞

搜索此博客

AllLink-Navi